Free Trial
TSE:CRDL

Cardiol Therapeutics Q4 2025 Earnings Report

Cardiol Therapeutics logo
C$1.46 0.00 (0.00%)
As of 06/12/2026 04:00 PM Eastern

Cardiol Therapeutics EPS Results

Actual EPS
-C$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cardiol Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cardiol Therapeutics Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cardiol Therapeutics Earnings Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More Cardiol Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiol Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your email.

About Cardiol Therapeutics

Cardiol Therapeutics (TSE:CRDL) ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299).

View Cardiol Therapeutics Profile